Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients 45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

Hirschbuehl Klaus; Labopin Myriam; Polge EmmanuelleBlaise DidierBourhis Jean HenriSocie GerardForcade EdouardYakoub-Agha IbrahimLabussiere-Wallet HeleneBethge WolfgangChevallier PatriceBonnet SarahStelljes MatthiasSpyridonidis AlexandrosPeric ZinaidaBrissot EoliaSavani BipinGiebel SebastianSchmid ChristophCiceri FabioNagler ArnonMohty Mohamad

首页> 外文期刊>Bone marrow transplantation >Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients 45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

【24h】

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients 45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

机译：Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients 45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Allogeneic hematopoietic cell transplantation is a potentially curative treatment in high-risk acute lymphoblastic leukemia (ALL). Conditioning regimens based on >= 12 Gray total body irradiation (TBI) represent the current standard in patients 45 years transplanted from matched donors in first complete remission, who had received either fludarabine/TBI 8 Gy (FluTBI8, n = 262), or the most popular, irradiation-free alternative fludarabine/busulfan, comprising busulfan 6.4 mg/kg (FluBu6.4, n = 188) or 9.6 mg/kg (FluBu9.6, n = 51). At two years, overall survival (OS) was 68.5%, 57%, and 62.2%, leukemia-free survival (LFS) was 58%, 42.7%, and 45%, relapse incidence (RI) was 27.2%, 40%, and 30.9%, and non-relapse-mortality (NRM) was 23.1%, 20.7%, and 26.8% for patients receiving FluTBI8Gy, FluBu6.4, and FluBu9.6, respectively. In multivariate analysis, the risk of NRM, acute and chronic graft-versus-host disease was not influenced by conditioning. However, RI was higher after FluBu6.4 (hazard ratio [HR] [95% CI]: 1.85 [1.16-2.95]), and LFS was lower after both FluBu6.4 (HR: 1.56 [1.09-2.23]) and FluBu9.6 (HR: 1.63 [1.02-2.58]) as compared to FluTBI8. Although only resulting in a non-significant advantage in OS, this observation indicates a stronger anti-leukemic efficacy of TBI-based intermediate intensity conditioning.

著录项

来源
《Bone marrow transplantation》 |2023年第8期|874-880|共7页
作者
Hirschbuehl Klaus; Labopin Myriam; Polge EmmanuelleBlaise DidierBourhis Jean HenriSocie GerardForcade EdouardYakoub-Agha IbrahimLabussiere-Wallet HeleneBethge WolfgangChevallier PatriceBonnet SarahStelljes MatthiasSpyridonidis AlexandrosPeric ZinaidaBrissot EoliaSavani BipinGiebel SebastianSchmid ChristophCiceri FabioNagler ArnonMohty Mohamad;
展开▼
作者单位

Augsburg Univ Hosp;

Med Fac;

Sorbonne UnivInst Paoli CalmettesGustave RoussyHop St LouisHop Haut levequeUniv LilleCtr Hosp Lyon SudUniv TubingenCHU NantesHop St EloiUniv Hosp MuensterUniv PatrasUniv PatrasUniv Hosp Ctr ZagrebHop St AntoineVanderbilt UnivMar Sklodowska Curie Natl Res Inst OncolUniv Vita Salute San RaffaeleChaim Sheba Med Ctr;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类治疗学;
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; CONSENSUS DEVELOPMENT PROJECT; VERSUS-HOST-DISEASE; REDUCED-INTENSITY; CLINICAL-TRIALS; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DIAGNOSIS; SURVIVAL; CRITERIA;

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients 45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

摘要

著录项

相关主题

期刊订阅